At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Blenrepdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
In Brief
An observational study evaluating Blenrep for Multiple Myeloma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
N/ACompletedFinished
202420252026
First PostedAug 2023
Enrollment StartSep 2023
Primary CompletionNov 2023
TodayJul 2026
First PostedAug 14, 2023
Enrollment StartSep 18, 2023
Primary CompletionNov 7, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.9 years ago
Interventions
Blenrepdrug
Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.